Cure SMA

New Report Card Shows Two-Thirds of U.S. States Now Screen for SMA, Leaving 1 in 3 American Newborns Still at Risk for Delayed Diagnosis

The Pediatric Neuromuscular Clinical Research Network Will Continue to Drive Treatment Development Under Cure SMA's Funding

Leading rare disease patient advocacy organizations will use real-world evidence to advance research, drug development, and access

Groundbreaking single-dose therapy will have live-saving impact for infants affected by spinal muscular atrophy.

Cutting-edge clinical data registry will help drive improvements in care for the leading genetic cause of death for infants under two years of age.

Legislation will help promote life-saving treatment of the leading genetic cause of death for infants under two years of age.

Recommendation will help promote life-saving treatment of the leading genetic cause of death for infants under two years of age.

Legislation will help promote life-saving treatment of the leading genetic cause of death for infants under two years of age.

Cure SMA is extremely pleased to announce a generous $620,000 gift has been made to the organization. The donation was made anonymously in honor of William N. Kanehann. Billy had SMA and died in 2013 at the age of 23.

Recommendation will help promote life-saving treatment of the leading genetic cause of death for infants under two years of age.